

**Development of a Novel
Co-vaccination Approach for
Pneumococcal and Influenza Infections**



Rachelle Babb, B. Sc. (Hons)

A thesis submitted for the fulfilment of the
Degree of Doctor of Philosophy

School of Biological Sciences
The University of Adelaide
Adelaide, South Australia, Australia

(May 2016)

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES	v
ABBREVIATIONS	vii
DECLARATION	x
ACKNOWLEDGEMENTS	xi
PATENTS, PUBLICATIONS AND CONFERENCE PRESENTATIONS ARISING FROM THIS THESIS	xiii
ABSTRACT	xiv

Chapter 1: Introduction

1.1 <i>Streptococcus pneumoniae</i>	2
1.1.1 Significance	2
1.1.2 Pneumococcal carriage and disease	3
1.1.3 Antibiotic treatment	4
1.1.4 Pathogenesis.....	4
1.1.5 Immunity	6
1.1.5.1 Innate immunity	6
1.1.5.2 Adaptive immunity	8
1.1.5.3 Complement and antibody-mediated immunity	9
1.1.6 Pneumococcal vaccines	10
1.1.6.1 Capsular Polysaccharide vaccines	10
1.1.6.2 Experimental vaccines	12
1.2 Influenza A Virus	14
1.2.1 Biology and pathogenesis	15
1.2.2 Immunity	17
1.2.2.1 Innate immunity	17
1.2.2.2 Adaptive immunity	18
1.2.3 Influenza Vaccines	20
1.3 Co-infection with influenza and <i>S. pneumoniae</i>	21
1.3.1 Mechanisms underlying synergism	22
1.3.2 Vaccination strategies against co-infection	24
1.4 Combination vaccines	25
1.5 Intranasal vaccination	26
1.6 Adjuvants for intranasal delivery	28
1.6.1 Enterotoxins	28
1.6.2 TLR agonists	29
1.6.3 Natural killer T (NKT) cell agonists	31
1.6.4 Delivery systems	31

1.7 Gamma-irradiation	32
1.7.1 Gamma-irradiation as an inactivation method for vaccines	32
1.7.2 Advantages of gamma-irradiation for pathogen inactivation	34
1.8 Research project	35
1.8.1 Project rationale	35
1.8.2 Hypotheses and Aims	37
Chapter 2: Material and methods	39
2.1 Bacterial strains and growth conditions	40
2.2 Viral stocks	40
2.3 Construction of the Rx1[PdT/ Δ LytA] vaccine strain	40
2.4 Generation of the gamma-irradiated Rx1[PdT/ Δ LytA] vaccine	41
2.5 Generation of the gamma-irradiated influenza vaccine	43
2.6 Western blotting	43
2.7 Hemolysis Assay	43
2.8 Gram staining	43
2.9 Scanning electron microscopy	43
2.10 Focus forming inhibition assay	44
2.11 Ethics statement	44
2.12 Vaccination	44
2.13 Adjuvants	45
2.14 Infection models	45
2.15 IFN- γ /IL-17 neutralization <i>in vivo</i>	46
2.16 CD4 depletion <i>in vivo</i>	46
2.17 Measurement of antibody responses	46
2.18 Splenocyte stimulation	47
2.19 Lung digestion to retrieve lymphocytes for flow cytometric analysis	48
2.20 Intracellular cytokine staining and flow cytometry	48
2.21 <i>In vivo</i> cytotoxic T cell assay	48
2.22 Statistics	49
Chapter 3: The efficacy of the γ-PN vaccine	51
3.1 Introduction	52
3.2 Results	53
3.2.1 Characterization and optimization of the γ -PN vaccine	53
3.2.2 Immunisation with γ -PN provides serotype-independent protection	61
3.2.3 γ -PN efficacy is dependent on B cell responses	64
3.2.4 IL-17 plays an essential role in the protective efficacy of γ -PN	66
3.2.5 Vaccination with γ -PN induces CD4-independent IL-17 immunity	66

3.3 Discussion	74
Chapter 4: The role of adjuvants in γ-PN vaccine efficacy	79
4.1 Introduction	80
4.2 Results	81
4.2.1 Intranasal vaccination with γ -PN + CT elicits optimal protection against pneumococcal challenge	81
4.2.2 Intranasal vaccination with γ -PN + CT enhances pneumococcal-specific antibody levels and induces Th17 cells	82
4.2.3 Intranasal vaccination with γ -PN + MC	90
4.3 Discussion	91
Chapter 5: Intranasal co-vaccination with γ-PN + γ-FLU	99
5.1 Introduction	100
5.2 Results	101
5.2.1 The immunogenicity and protective efficacy of γ -FLU	101
5.2.2 Co-immunisation enhances the protective efficacy of the γ -PN vaccine	107
5.2.3 Cellular immunity plays a major role in the observed enhanced protection elicited by co-immunisation.	111
5.2.4 Co-immunisation enhances pneumococcal-specific memory Th17 and Th1 cell responses	114
5.2.5 Co-immunisation promotes tissue-resident memory cell development.....	114
5.2.6 Co-immunisation promotes Th17 and CD4 ⁺ TRM IL-17 ⁺ cell responses to live pneumococcal challenge	115
5.2.7 Co-immunisation enhances IFN- α levels following live pneumococcal challenge	120
5.2.8 Co-immunisation does not compromise the protective efficacy of γ -FLU	120
5.2.9 Co-immunisation elicits significant protection against co-infection	129
5.3 Discussion	132
Chapter 6: Final discussion.....	137
6.1 Future directions	140
References.....	143
Appendix.....	173

LIST OF FIGURES & TABLES

- Figure 1.1** *S. pneumoniae* structure and virulence factors.
- Figure 1.2** Influenza structure.
- Figure 1.3** Mechanisms underlying influenza and bacterial co-infection.
- Figure 1.4** Intranasal administration and induction of mucosal immune responses.
- Table 2.1** PCR primers.
- Figure 3.1** Expression of PdT and LytA and hemolytic activity of the vaccine strain Rx1[PdT/ Δ LytA].
- Figure 3.2** Sterility testing of the gamma-irradiated vaccine strain Rx1[PdT/ Δ LytA].
- Figure 3.3** High doses of gamma-irradiation may affect the integrity of the cell membrane.
- Figure 3.4** Gamma-irradiation does not affect the morphology of *S. pneumoniae*.
- Figure 3.5** Higher doses of gamma-irradiation appear to affect the immunogenicity of vaccine preparations.
- Figure 3.6** Protection against sepsis elicited by immunization with γ -PN.
- Figure 3.7** Protection against focal pneumonia elicited by immunization with γ -PN.
- Figure 3.8** The efficacy of the γ -PN vaccine is dependent on B cell responses.
- Figure 3.9** Depletion of IL-17, but not IFN- γ abrogates protection induced by γ -PN.
- Figure 3.10** γ -PN does not induce antigen-specific Th17 cells.
- Figure 3.11** γ -PN does not induce tissue-resident memory cells.
- Figure 3.12** Vaccination with γ -PN induces IL-17 via $\gamma\delta$ T cells, not CD4⁺ T cells.
- Figure 4.1** Intranasal vaccination with γ -PN + CT enhances the protective efficacy of the γ -PN vaccine.
- Figure 4.2** Intranasal vaccination with γ -PN + CT does not elicit protection against nasopharyngeal colonization.
- Figure 4.3** Intranasal vaccination with γ -PN + CT is associated with enhanced pneumococcal-specific antibody titres.
- Figure 4.4** Intranasal vaccination with γ -PN + CT induces antigen-specific Th17 cells.
- Figure 4.5** Intranasal vaccination with γ -PN + CT promotes the development of TRM cells.
- Figure 4.6** Intranasal vaccination with γ -PN + MC does not alter γ -PN vaccine efficacy.
- Figure 4.7** Using a reduced dose of MC is not associated with significant enhancement in γ -PN vaccine efficacy.
- Figure 4.8** Intranasal vaccination with γ -PN + MC does not have a significant impact on γ -PN vaccine immunogenicity.

- Figure 5.1** Intranasal vaccination with γ -FLU provides homotypic protection against A/PR8 challenge.
- Figure 5.2** Intranasal vaccination with γ -FLU provides heterosubtypic protection against A/PC challenge.
- Figure 5.3** γ -FLU induces effective antibody responses.
- Figure 5.4** γ -FLU induces effective cytotoxic T cell responses.
- Figure 5.5** Co-vaccination with γ -PN + γ -FLU does not affect the protective efficacy of γ -PN vaccine against D39 challenge.
- Figure 5.6** Co-vaccination with γ -PN + γ -FLU enhances the vaccine efficacy of γ -PN.
- Figure 5.7** Co-vaccination with γ -PN + γ -FLU mediates protection against nasopharyngeal colonization.
- Figure 5.8** Co-vaccination with γ -PN + γ -FLU enhances pneumococcal-specific antibody titres.
- Figure 5.9** The protective efficacy of the combination vaccine is dependent on CD4⁺ responses.
- Figure 5.10** Co-immunisation with γ -PN + γ -FLU enhances memory pneumococcal-specific Th17 and Th1 cells.
- Figure 5.11** Co-vaccination with γ -PN + γ -FLU induces CD4⁺ and CD8⁺ TRM cells.
- Figure 5.12** Co-vaccination with γ -PN + γ -FLU induces Th17 and CD4⁺ TRM cells following live D39 challenge.
- Figure 5.13** Co-vaccination with γ -PN + γ -FLU enhances IFN-I levels following live D39 challenge.
- Figure 5.14** Co-immunisation with γ -PN + γ -FLU does not compromise vaccine-induced anti-influenza immunity.
- Figure 5.15** Co-immunisation with γ -PN + γ -FLU enhances influenza-specific memory Th17 cells.
- Figure 5.16** Co-immunisation with γ -PN + γ -FLU does not affect the level of influenza-specific humoral responses.
- Figure 5.17** Co-vaccination with γ -FLU + γ -PN does not compromise the neutralising ability of influenza-specific antibodies.
- Figure 5.18** Co-infection with influenza and *S. pneumoniae* enhances bacterial loads.
- Figure 5.19** Co-immunisation with γ -PN + γ -FLU provides significant protection against co-infection.

ABBREVIATIONS

A ₄₀₅	Absorbance at 405 nm
A ₄₅₀	Absorbance at 450 nm
ABC	ATP-binding cassette
ANT3	Adenine nucleotide translocator 3
APC	Antigen presenting cells
A/PC	A/Port Chalmers/1/73 [H3N2]
A/PR8	A/Puerto Rico/8/34 [H1N1] influenza strain
CbpA	Choline-binding protein A
CD	Cluster of differentiation
CFU	Colony forming unit
ChoP	Phosphorylcholine
CPG ODN	Cytosine phosphate guanosine oligodeoxynucleotides
CPS	Capsular polysaccharides
CRP	C-reactive protein
CTL	Cytotoxic T lymphocytes
CT	Cholera toxin
DC	Dendritic cell
DI	Dry ice
DMEM	Dulbecco' Modified Eagle's Medium
DTaP	Diphtheria-tetanus-acellular pertussis vaccine
Eno	Enolase
FACS	Fluorescent activated cell sorting
FCS	Foetal Calf Serum
FcR	Fc Receptor
FFI	Focus forming inhibition
Foxp3	Forkhead box P3
HA	Hemagglutinin
Hep B	Hepatitis B virus
Hib	<i>Haemophilus influenzae</i> type b
HPV	Human papilloma virus
HRP	Horse Radish Peroxidase
IFN-I	Type I Interferon (α/β)
IL-	Interleukin
IFN	Interferon
IFN- γ	Interferon gamma
Ig	Immunoglobulin
IN	Intranasally
IP	Intraperitoneally
IPD	Invasive pneumococcal disease
IPV	Inactivated poliovirus
IRF	Interferon regulatory factors
IV	Intravenously
KO	Knock out
kGy	kiloGray
LAIV	Live attenuated influenza vaccines
LT	Labile toxin
LytA	Autolysin

M1/2	Matrix protein 1/2
MARCO	Macrophage receptor with collagenous structure
M cells	Microfold cells
MC	Mannosylated Chitosan
MFI	Mean fluorescence intensity
mg	milligram/s
MHC	Major histocompatibility complex
mL	millilitre/s
MMR	Measles, Mumps and Rubella vaccine
MPL	Monophosphoryl lipid A
NA	Neuraminidase
NALT	Nasopharynx-associated lymphoid tissue
NEP	Nuclear Export Protein
NF-	Nuclear Factor
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NK	Natural Killer cell
NKT	Natural Killer T cell
NLR	Nod-like receptor/s
NP	Nucleoprotein
NPP	Nucleoprotein peptide
NS1	Non-structural protein 1
OD	Optical density
PA	Acidic polymerase
PAFr	Platelet-activating factor receptor
PAMPs	Pathogen associated molecular patterns
PavA	Pneumococcal adhesion and virulence A
PB1/2	Basic polymerase protein 1/2
PBS	Phosphate buffered saline
PBPs	Penicillin Binding proteins
PCR	Polymerase chain reaction
PCVs	Pneumococcal conjugate vaccines
PdT	Pneumolysin mutant
PhtD	Pneumococcal histidine triad D
PhtE	Pneumococcal histidine triad E
Ply	Pneumolysin
PKR	Protein Kinase R
PsaA	Pneumococcal surface antigen A
PspA	Pneumococcal surface protein A
PspC	Pneumococcal surface protein C
RNA	Ribonucleic acid
RNP	Ribonucleoprotein
PRR	Pattern recognition receptor
RT	Room temperature
RIG	Retinoic acid-inducible gene like receptors
<i>S. pneumoniae</i>	<i>Streptococcus pneumoniae</i>
<i>S. aureus</i>	<i>Staphylococcus aureus</i>
SD	Standard deviation
SFV	Semliki Forest Virus
ssRNA	Single-stranded ribonucleic acid

TCID ₅₀	50% tissue culture infective dose
TCR	T Cell receptor
Tfh	Follicular CD4 ⁺ T helper
Th17	CD4 ⁺ T helper 17
Th1	CD4 ⁺ T helper 1
THY	Todd-Hewitt broth
TLR	Toll-like receptor
TNF	Tumour Necrosis Factor
TRM	Tissue resident memory
WC	Whole-cell
WCV	Whole-cell vaccine
WT	Wild type
α-GalCer	Alpha-galactosylceramide
μg	microgram/s
μL	microlitre/s
γδ T	Gamma-delta T
γδ T17	Gamma-delta T cells secreting IL-17 ⁺
γ-FLU	Gamma-irradiated influenza vaccine
γ-PN	Gamma-irradiated <i>Streptococcus pneumoniae</i> vaccine
γ-SFV	Gamma-irradiated Semliki Forest vaccine

DECLARATION

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Rachelle Babb

Date

ACKNOWLEDGEMENTS

Firstly, I would like to thank my principle supervisor Dr Mohammed Alsharifi for the continuous support you have provided me from the very beginning when I started as an honours student in your lab in 2011. I have greatly appreciated your guidance and encouragement throughout the years. Thank you also for your compassion, motivational chats and your reassurance at times when I was feeling overwhelmed.

Secondly, I would also like to sincerely thank Professor James Paton for your continuous guidance with experimental designs, your willingness to answer my questions, your advice and overall supervision throughout the project. I would also like to extend my gratitude to my other co-supervisor Dr David Ogunniyi for your supervision and for teaching me my very first techniques in bacteriology.

I would also like to especially thank Dr Austen Chen, I have thoroughly enjoyed working with you over the years and greatly appreciate all the help you have provided me not only scientifically but emotionally as well. Thank you for always making me laugh amongst the many hours spent in the animal house. Your inability to remember my colour coding for mice experiments to this day still amazes me.

A special thanks to Professor Tim Hirst and Gamma Vaccines Pty Ltd for providing me with funding for the project and for the continuous support over the years. I am very fortunate to be part of the gamma-irradiated pneumococcal vaccine team and sincerely thank you for taking me on board.

To all past and present members of the Alsharifi lab, especially Josy, Nikki, Sha, Jenny, Shannon, Eve and Cheng. Thank you for your support, friendship and lovely company. It has been a great pleasure sharing this experience with all of you. Particularly Josy and Nikki, thank you for your friendship, offering me a helping hand, providing me emotional support on those difficult experimental days, providing endless amount of food and for overall making the lab environment a lot of fun. The memories we have shared will be remembered always. In addition I would also like to thank Rethish from the Connor lab for the great company, motivational chats and friendship.

To all past and present members of the Paton lab especially Claudia, Catherine, Richard, Charlie, Layla, Danny and Brock. Thank you for all being so friendly, welcoming me into the

lab and for helping me with experimental techniques. A special thanks to Claudia, Richard and Brock for your assistance in mice challenge studies.

I would also like to extend my thanks to Prof Shaun McColl for your assistance in experimental designs and to Lynn Waterhouse for the help provided with SEM.

Most importantly, a big thank you goes to my parents, and my siblings Anthony and Belinda. Thank you for your patience and understanding during the difficult times I endured over the years and the continuous support. Mum and Dad you have been so supportive of me not only these past few years but from a very young age. I am very fortunate to have such loving parents and want to let you know I greatly appreciate you both being there for me. I love you dearly. To my other dear friends (you know who you are), thank you for your emotional support throughout these past few years and for being so understanding when I had mice experiments I needed to attend to at all hours of the day.

Last but not least, I would like to especially thank Ervin. I am so glad that I was able to experience this journey with you by my side. I have greatly appreciated your encouragement throughout all of these years, your emotional support and for always making me laugh at the best and worst of times. I look forward to sharing many more years together.

PATENTS, PUBLICATIONS AND CONFERENCE PRESENTATIONS ARISING FROM THIS THESIS

PATENTS		
Patent application No	Title	Inventors
PCT/AU2016/050231	Streptococcal Vaccine	Rachelle Babb, Mohammed Alsharifi, Austen Yannis Chen, Shannon Christa David, Timothy Raymond Hirst, Abiodun David Ogunniyi, James Cleland Paton

PUBLICATIONS		
Thesis chapter	Title	Publication status
3	Intranasal vaccination with gamma-irradiated <i>Streptococcus pneumoniae</i> whole-cell vaccine provides serotype-independent protection mediated by B cells and innate IL-17 responses *Appendix	Published
5	Enhanced protective CD4+ T cell responses to a serotype independent pneumococcal vaccine when combined with an inactivated influenza vaccine	In submission

CONFERENCE PRESENTATIONS	
<ul style="list-style-type: none"> • The 12th European Meeting on the Molecular Biology of the Pneumococcus (Oxford University, Oxford, UK, 2015). 	Poster
<ul style="list-style-type: none"> • School of Biological Sciences Research Symposium (University of Adelaide, Adelaide, Australia, 2013-2014). 	Presentation

ABSTRACT

Streptococcus pneumoniae and influenza are the world's foremost bacterial and viral respiratory pathogens. In addition to their individual clinical significance, co-infection with these pathogens enhances disease progression and is associated with substantially increased mortality rates. Vaccination is the best preventative method to control disease caused by individual pathogens as well as co-infection. Gamma-irradiation is considered a safe sterilization method, used routinely to sterilize medical devices, pharmaceuticals and most commonly food products. It can also be utilised as an inactivation technique to generate whole cell bacterial and viral vaccines with minimal impact on pathogen structure and antigenic determinants. This study presents the first evidence illustrating the use of this inactivation technique for development of a mucosal *S. pneumoniae* whole cell vaccine (γ -PN). Gamma-irradiation was utilised to inactivate an unencapsulated *S. pneumoniae* strain Rx1 with an unmarked deletion of the autolysin gene and with the pneumolysin gene replaced with an allele encoding a non-toxic pneumolysoid. Intranasal administration of mice with γ -PN without an adjuvant was shown to elicit serotype-independent protection against pneumococcal challenge in models of sepsis and pneumonia. In particular, vaccine efficacy was shown to be reliant on B cells and IL-17 responses. Importantly, immunisation promoted IL-17 production by $\gamma\delta$ T cells, as opposed to conventional Th17 cells commonly reported with other pneumococcal whole cell vaccines. Moreover, this study also illustrated that the immunogenicity and protective efficacy of the γ -PN vaccine can be enhanced in the presence of the mucosal adjuvant, cholera toxin.

In addition, this study describes a novel combination vaccine approach comprising inactivated whole bacterial cells and whole virions to *S. pneumoniae* and influenza respectively. In this study mice were co-immunised intranasally with the un-adjuvanted γ -PN vaccine and a gamma-irradiated influenza vaccine (γ -FLU). Interestingly, co-immunisation was shown to enhance γ -PN vaccine efficacy and immunogenicity against virulent pneumococcal challenge, which was dependent on CD4⁺ T cell responses. In contrast to vaccination with γ -PN alone, co-immunisation enhanced pneumococcal-specific effector Th17 and Th1 memory cells, promoted development of CD4⁺ tissue-resident memory cells, and enhanced pneumococcus-specific antibody responses. In addition, this combination approach was shown to elicit significant protection against lethal influenza challenge, as well

as against co-infection with both influenza and *S. pneumoniae*. These data support the notion that γ -FLU exhibits adjuvant-like properties to enhance immunogenicity of a co-administered vaccine without compromising pathogen-specific immune responses. Future work will be focused on clinical development of individual and combination vaccines.